Implementation of Cancer Genomics in the United States: Views of Payers and Other Stakeholders on Challenges and the Role of Payers in Solutions.

Purpose: Genomic testing is crucial in cancer risk identification, diagnosis, and treatment. However, health care implementation is challenging, even for tests covered by insurance. US payers are important health care participants and may contribute to addressing implementation challenges.

Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in , , or .

Purpose: Oncologists encounter patients with pathogenic variants (PVs) in , , or , but little is known about their cancer mortality.

Methods: Patients who were 20 years or older, diagnosed in 2013-2019 with breast, colorectal, or pancreatic cancer, and reported to SEER registries in California and Georgia were linked to germline genetic testing results from four clinical laboratories and followed through 2021. Multivariable models of cancer mortality were fit; for each cancer, the reference group was the average hazard across all genetically tested patients with that diagnosis.

The Genetic Information and Family Testing (GIFT) study: trial design and protocol.

Background: There is pressing need to develop and evaluate clinically sound approaches to supporting the engagement between patients who have inherited cancer susceptibility and their relatives who may share it. Identifying and engaging patients with an inherited cancer susceptibility in the community is a potentially powerful strategy to reduce the gap in genetic risk evaluation for their families. The goal of the Genetic Information and Family Testing (GIFT) Study is to engage patients about inherited cancer susceptibility and provide support and services to their relatives to initiate genetic risk evaluation (including choice of home genetic testing).